Navigation Links
Framingham Study Shows Parents Who Live Long Pass On Lower Risk of,Cardiovascular Disease

BETHESDA, Md., March 13, 2007--New evidence suggests that if you could choose your parents, you could reduce your risk of cardiovascular disease. Researchers from the long-standing Framingham Heart Study (FHS), a program of the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health, report that people whose parents live longer were more likely to avoid developing high blood pressure, high cholesterol, and other risk factors for cardiovascular disease in middle age than their peers whose parents died younger. They also found that the risk factor advantages persisted over time.

According to the researchers, this is the first study to examine cardiovascular risk factors in the offspring of longer-lived individuals using independent and validated measurements of risk. The findings are consistent with other studies that have linked lower cardiovascular risk with parental longevity based on self-reports of family history.

"Characteristics of Framingham Offspring Participants with Long-Lived Parents, appears in the March 12 issue of the Archives of Internal Medicine.

In the study, researchers examined 1,697 offspring age 30 and older (average age 40) whose parents participated in the original FHS and had reached age 85 or died before January 1, 2005. They compared cardiovascular risk factors among the offspring based on whether both parents, one parent, or neither parent lived to 85 years or older. The risk factors included age, sex, education, cigarette smoking, blood pressure, cholesterol, and body mass index (BMI). In addition, they compared the offsprings' Framingham Risk Scores, a summary score based on the combined contribution of traditional cardiovascular risk factors.

In general, the group in which both parents survived to age 85 had significantly fewer participants with high blood pressure or who were current smokers, compared to those in which both parents or one parent had died. In addition, the middle-aged children of long-lived parents had significantly lower levels of blood pressure and blood cholesterol, and they had lower Framingham Risk Scores than those in which one or both parents had died. Overall, parental longevity did not significantly affect BMI. After 12 years of follow up, the offspring of longer-lived parents were also less likely to progress to high blood pressure and to generate higher risk scores, the researchers report.

NHLBI's Framingham Heart Study has studied the health of many of the Massachusetts towns residents since 1948. The community-based research program has been the source of key research findings regarding the contributions of hypertension, high cholesterol, cigarette smoking, and other risk factors to the development of cardiovascular disease. Now assessing a third generation of participants, Framingham Heart Study investigators are expanding their research into other areas such as the role of genetic factors in cardiovascular disease as well as the use of novel biomarkers and new diagnostic tests to identify individuals at high risk.

Daniel Levy, M.D., Director of the Framingham Heart Study, and other FHS investigators are available to comment on the study's findings as well as how modifiable risk factors can lower cardiovascular disease risk.

To schedule interviews, contact the NHLBI Communications Office at 301-496-4236.

RESOURCES:

Part of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NH LBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders. The Institute also administers national health education campaigns on women and heart disease, healthy weight for children, and other topics. NHLBI press releases and other materials are available online at www.nhlbi.nih.gov.

The National Institutes of Health (NIH) — The Nation's Medical Research Agency — includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.


CONTACT:
NHLBI Communications Office
301-496-4236
'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 14, 2017 The Bio Supply Management Alliance ... of Fremont and the Biomedical Manufacturing Network ... in California by providing a ... and fostering workforce development. The primary focus of this ... start-ups, as well as small and mid-sized biomedical companies. ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
(Date:6/8/2017)... MAITLAND, Fla. , June 8, 2017  Less ... ransomware attack that hit more than 200,000 companies, including hospital ... is being heralded as one of the largest online ... technology in the healthcare market, it is imperative that ... can protect their data from this — and many ...
Breaking Medicine Technology:
(Date:6/28/2017)... , ... June 28, 2017 , ... With the onset of long work hours and ... fractures due to falls at work and at home will only continue to grow unless ... are not following proper safety procedures, a fall at work or home can lead to ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... technology makes it possible to see through objects, has announced the winners of ... consumer apps with its fully programmable, Raspberry Pi-enabled 3D sensor, Walabot . ...
(Date:6/28/2017)... ... , ... As we celebrate our nation’s independence, many Americans will gather around ... time to celebrate National Hot Dog Month. The National Hot Dog and Sausage ... 4th alone and while they enjoy many different kinds of hot dogs, research commissioned ...
(Date:6/28/2017)... ... 2017 , ... Quorum Health announced that Robert A. Vento has been appointed ... Maher was promoted to COO of QHR. , A national search was ... and CEO in December 2016. , “I’m pleased to announce these ...
(Date:6/28/2017)... ... June 28, 2017 , ... The parent company ... in employee engagement. Omaha-based C&A Industries, a national leader in staffing and ... in North America for 2017. The annual award, issued by Achievers, ...
Breaking Medicine News(10 mins):